2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T70f,Sunscreen use has known benefits, including decreasing the risk of developing skin cancer and photoaging. Previous studies have reported that the amount of sunscreen used decreased with increased unit price and that individuals underapply sunscreen. To assess how the cost of recommended sunscreen use varies depending on unit price and the other sun protective behaviors. In this economic evaluation study conducted from July 14 to August 31, 2025, sunscreen application costs were calculated based on recommended application amounts, use of other sun protection strategies, and 2025 sunscreen prices. The primary outcome was the annual cost of applying sunscreen based on recommended application amounts, use of other sun protection strategies, and 2025 sunscreen prices from an online retailer. For sunscreens with similar ingredients and sun protection factor ratings, the unit price of sunscreen varied by up to 17.5-fold across 3 sunscreens. Cost per application varied from $0.04 to $3.79 depending on wearing different combinations of typical clothing, whereas 1 year of sunscreen use was estimated to cost between $39.28 and $1429.42, a 36-fold difference, depending on unit price and other sun protective strategies used. A single week of sunscreen use at the beach, assuming 2 applications a day, costs approximately $6.57 to $135.82, depending on whether wearing shorts or a bikini and sunscreen unit price. These findings suggest that the cost of applying sunscreen at the recommended amounts varies significantly depending on unit price and the concurrent use of other sun protective strategies. Decreasing the potential cost by encouraging the use of other sun protective strategies and lower-priced sunscreens could facilitate compliance and reduction in the risk of developing skin cancers.31:Tb28, Importance Sunscreen use has known benefits, including decreasing the risk of developing skin cancer and photoaging. Previous studies have reported that the amount of sunscreen used decreased with increased unit price and that individuals underapply sunscreen. Objective To assess how the cost of recommended sunscreen use varies depending on unit price and the other sun protective behaviors. Design and Setting In this economic evaluation study conducted from July 14 to August 31, 2025, sunscreen application costs were calculated based on recommended application amounts, use of other sun protection strategies, and 2025 sunscreen prices. Main Outcomes and Measures The primary outcome was the annual cost of applying sunscreen based on recommended application amounts, use of other sun protection strategies, and 2025 sunscreen prices from an online retailer. Results For sunscreens with similar ingredients and sun protection factor ratings, the unit price of sunscreen varied by up to 17.5-fold across 3 sunscreens. Cost per application varied from $0.04 to $3.79 depending on wearing different combinations of typical clothing, whereas 1 year of sunscreen use was estimated to cost between $39.28 and $1429.42, a 36-fold difference, depending on unit price and other sun protective strategies used. A single week of sunscreen use at the beach, assuming 2 applications a day, costs approximately $6.57 to $135.82, depending on whether wearing shorts or a bikini and sunscreen unit price. Conclusions and Relevance These findings suggest that the cost of applying sunscreen at the recommended amounts varies significantly depending on unit price and the concurrent use of other sun protective strategies. Decreasing the potential cost by encouraging the use of other sun protective strategies and lower-priced sunscreens could facilitate compliance and reduction in the risk of developing skin cancers. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Economic Evaluation: study design Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Economic Evaluation (study design). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/study_design/Economic%20Evaluation\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study Designs\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Economic Evaluation\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design/Economic%20Evaluation\"}]}}"}}]],["$","$L2f",null,{"title":"Economic Evaluation: Research & Clinical Takeaways","description":"Browse Economic Evaluation research papers with clear, practical takeaways for your clinical practice.","papers":[{"doi":"10.1001/jamadermatol.2026.2633","pmid":"42555037","title":"Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-08-05T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13445090/","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:05.687Z","updated_at":"2026-08-12T13:26:05.687Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"IL-17A/F Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"modality","value":"TNF-alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sample_size","value":"n=6","value_numeric":6},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Bimekizumab brand name 'Bimzelx' assumed based on known regulatory approval; not explicitly stated in the source text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Full text was inaccessible; summary is based solely on the abstract and results excerpt. Methodological nuances (e.g., discounting, time horizon, sensitivity analyses beyond severity adjustment) could not be verified.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Level of evidence assigned as 4 (economic/decision analysis); no direct clinical trial was conducted in this study.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2633","tag_type":"warning","value":"Sample size tag reflects 6 Phase 3 trials used for efficacy data synthesis, not a patient-level N — no total patient count was reported in the available abstract.","value_numeric":null}],"summaries":{"what_studied":"This economic evaluation compared the cost-efficiency of three approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS) — adalimumab, secukinumab, and bimekizumab — across five countries (US, Canada, France, Germany, Australia) using Phase 3 trial efficacy data and publicly available drug pricing as of January 31, 2026.","key_result":"Adalimumab 40 mg weekly was on the efficiency frontier in all five countries for both HiSCR-50 and HiSCR-75 outcomes. Secukinumab 300 mg every 4 weeks reached the frontier only when US wholesale acquisition costs were used. Annual costs ranged from $11,345 (adalimumab in Australia) to $411,990 (bimekizumab in the US).","limitations":"- Only publicly available list prices were used; negotiated or rebated prices, which vary widely, were not included.\n- Efficacy data were drawn from separate Phase 3 trials without head-to-head comparisons, limiting direct cross-drug efficacy inference.\n- Full-text access was unavailable; some methodological details may be incomplete.","practice_takeaway":"Adalimumab remains the most cost-efficient approved biologic for HS across major health systems, with costs up to 36-fold lower than bimekizumab in the US. Clinicians and payers advocating for value-based formulary decisions should weigh these large pricing differentials alongside efficacy data."}},{"doi":"10.1001/jamasurg.2026.2185","pmid":"42340701","title":"Financial Comparison of Single- vs 2-Stage Management of Bile Duct Stones","journal_title":"JAMA Surgery","journal_issn":"2168-6254","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1001/jamasurg.2026.2185","source_score":13,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-27T13:27:32.471Z","updated_at":"2026-06-27T13:27:32.471Z","tags":[{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"condition","value":"Bile Duct Stones","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"condition","value":"Choledocholithiasis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"warning","value":"Only the abstract was provided — no specific cost figures, sample sizes, reimbursement data, or study conclusions are available for extraction. All key result and practice takeaway fields are set to null due to insufficient data.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"warning","value":"Paper is dated June 24, 2026, which is 3 days before today's date — may be an advance online publication with limited indexing.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.2185","tag_type":"warning","value":"Study design labeled as 'Economic Evaluation'; it is unclear whether a decision-analytic model, retrospective cost analysis, or another method was used.","value_numeric":null}],"summaries":{"what_studied":"This economic evaluation compared the costs, reimbursements, and estimated net operating margins of single-stage vs 2-stage strategies for bile duct stone clearance.","limitations":"Abstract only — no sample size, specific cost figures, or outcome data are reported. Clinical effectiveness is not assessed."}},{"doi":"10.1001/jamadermatol.2025.6150","pmid":"41706462","title":"Sunscreen Costs in Association With Sun Protective Behaviors","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-02-18T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12917738/","source_score":99,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-19","doi":"10.1001/jamadermatol.2025.6150","days":"30","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"99","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.6150","title":"Sunscreen Costs in Association With Sun Protective Behaviors.","journal":"JAMA dermatology","methods":"","results":"For sunscreens with similar ingredients and sun protection factor ratings, the unit price of sunscreen varied by up to 17.5-fold across 3 sunscreens. Cost per application varied from $0.04 to $3.79 depending on wearing different combinations of typical clothing, whereas 1 year of sunscreen use was estimated to cost between $39.28 and $1429.42, a 36-fold difference, depending on unit price and other sun protective strategies used. A single week of sunscreen use at the beach, assuming 2 applications a day, costs approximately $6.57 to $135.82, depending on whether wearing shorts or a bikini and sunscreen unit price.","abstract":"$30","keywords":[],"pubmed_id":"41706462","conclusions":"","publication_date":"2026-02-18T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.6150","URL":"https://doi.org/10.1001/jamadermatol.2025.6150","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2845201/jamadermatology_mundada_2026_br_250015_1775760814.2736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"402","type":"journal-article","issue":"4","score":1,"title":["Sunscreen Costs in Association With Sun Protective Behaviors"],"author":[{"given":"Maya","family":"Mundada","sequence":"first","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}]},{"given":"Jeffrey","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Maria L.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"San Francisco VA Health Care System, San Francisco, California"},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}]}],"issued":{"date-parts":[[2026,4,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"162","created":{"date-time":"2026-02-18T16:30:35Z","timestamp":1771432235000,"date-parts":[[2026,2,18]]},"indexed":{"date-time":"2026-04-15T15:51:18Z","timestamp":1776268278936,"date-parts":[[2026,4,15]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2845201"}},"subtitle":[],"deposited":{"date-time":"2026-04-15T15:00:26Z","timestamp":1776265226000,"date-parts":[[2026,4,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,4,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1177/10781552251327596","key":"dbr250015r1","year":null,"issue":null,"author":"Micha","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"J Oncol Pharm Pract","doi-asserted-by":"publisher"},{"DOI":"10.7326/0003-4819-158-11-201306040-00002","key":"dbr250015r2","year":"2013","issue":"11","author":"Hughes","volume":"158","first-page":"781","unstructured":null,"article-title":"Sunscreen and prevention of skin aging: a randomized trial.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.02.1112","key":"dbr250015r3","year":"2015","issue":"1","author":"Holman","volume":"73","first-page":"83","unstructured":null,"article-title":"Patterns of sunscreen use on the face and other exposed skin among US adults.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.7759/cureus.84783","key":"dbr250015r4","year":"2025","issue":"5","author":"Tatliparmak","volume":"17","first-page":null,"unstructured":null,"article-title":"Sunscreen use and photoprotection practices: a cross-sectional survey of adults in a dermatology outpatient clinic.","journal-title":"Cureus","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2019.1587147","key":"dbr250015r5","year":"2020","issue":"4","author":"Weig","volume":"31","first-page":"403","unstructured":null,"article-title":"Assessing factors affecting sunscreen use and barriers to compliance: a cross-sectional survey-based study.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2025.01.007","key":"dbr250015r6","year":"2025","issue":"5","author":"Fernandez","volume":"92","first-page":"1103","unstructured":null,"article-title":"Affordability matters: a cross-sectional study on sunscreen cost and application amount.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.06.043","key":"dbr250015r7","year":"2011","issue":"3","author":"Mahé","volume":"65","first-page":"e73","unstructured":null,"article-title":"Are sunscreens luxury products?","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr250015r8","year":"2014","issue":null,"author":"Johal","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Dermatol Online J","doi-asserted-by":null},{"DOI":"10.4266/acc.2019.00647","key":"dbr250015r9","year":"2019","issue":"4","author":"Murari","volume":"34","first-page":"276","unstructured":null,"article-title":"Lund and Browder chart–modified versus original: a comparative study.","journal-title":"Acute Crit Care","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1475-097X.2006.00718.x","key":"dbr250015r12","year":"2007","issue":"3","author":"Heaf","volume":"27","first-page":"135","unstructured":null,"article-title":"The origin of the 1 x 73-m2 body surface area normalization: problems and implications.","journal-title":"Clin Physiol Funct Imaging","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.2012.04388.x","key":"dbr250015r13","year":"2012","issue":"8","author":"Teramura","volume":"37","first-page":"904","unstructured":null,"article-title":"Relationship between sun-protection factor and application thickness in high-performance sunscreen: double application of sunscreen is recommended.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-022-02467-4","key":"dbr250015r14","year":"2023","issue":"4","author":"Hanna","volume":"315","first-page":"925","unstructured":null,"article-title":"Cost and quality in consumer sunscreen preferences.","journal-title":"Arch Dermatol Res","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr250015r15","year":"2018","issue":"1","author":"Ouyang","volume":"17","first-page":"116","unstructured":null,"article-title":"Realistic sunscreen durability: a randomized, double-blinded, controlled clinical study.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"dbr250015r10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Calvo? T. Best and Worst Sunscreens of 2025. Consumer Report. Published online June 3, 2025. Accessed August 8, 2025. https://www.consumerreports.org/health/sunscreens/best-sunscreens-of-the-year-a7763432372/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dbr250015r11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Walmart.com. Walmart. Accessed July 16, 2025. https://www.walmart.com","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2026,4,1]]},"reference-count":15,"published-online":null,"references-count":15,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.6150","is_oa":true,"title":"Sunscreen Costs in Association With Sun Protective Behaviors","updated":"2026-02-22T08:08:42+00:00","published_date":"2026-02-18","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12917738/","pmh_id":"oai:pubmedcentral.nih.gov:12917738","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12917738/"}}},"created_at":"2026-05-07T17:34:01.653Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"condition","value":"Photoaging","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"condition","value":"Skin Cancer","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"modality","value":"Sunscreen / Photoprotection","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"warning","value":"Full text is under embargo until February 18, 2027; summary is based solely on the abstract and reported results. Additional methodology details (e.g., which specific sunscreens were selected, exact body surface area calculations) are not available for review.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"warning","value":"No sample size (N) is applicable — this is an economic/cost modeling study, not a clinical trial with enrolled participants.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.6150","tag_type":"warning","value":"Study design label 'Economic Evaluation' may broadly encompass cost modeling; no clinical outcomes were directly measured.","value_numeric":null}],"summaries":{"what_studied":"This economic evaluation assessed how the annual and per-application cost of sunscreen varies based on unit price, recommended application amounts, and use of other sun protective behaviors (e.g., clothing coverage), using 2025 retail prices for three sunscreens with similar ingredients and SPF ratings.","key_result":"Unit price varied up to 17.5-fold across the three sunscreens; cost per application ranged from $0.04 to $3.79 depending on clothing worn. Annual sunscreen cost ranged from $39.28 to $1,429.42 (a 36-fold difference). One week of beach use (2 applications/day) cost $6.57–$135.82 depending on body coverage and sunscreen price.","limitations":"Only three sunscreens from a single online retailer were evaluated, limiting generalizability. The study does not account for variable consumer behavior, sunscreen type (spray vs. lotion), or income-related access barriers.","practice_takeaway":"Counsel patients that pairing lower-cost sunscreens with physical sun protection (hats, UPF clothing) can dramatically cut annual sunscreen costs and may improve adherence. Recommending affordable sunscreen options alongside other sun-safe behaviors is a practical, low-barrier strategy to reduce skin cancer risk."}},{"doi":"10.1001/jamadermatol.2025.5498","pmid":"41533361","title":"Advanced Practice Clinicians and Dermatology Drug Spending","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-01-14T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12805487/","source_score":14,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1001/jamadermatol.2025.5498","days":"7","issn":"2168-6068","rank":"7","field":"Clinical Medicine","score":"14","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.5498","title":"Advanced Practice Clinicians and Dermatology Drug Spending.","journal":"JAMA dermatology","methods":"","results":"","abstract":"This economic evaluation study uses Medicare Part D data to assess the association between advanced practice clinicians and drug spending trends in dermatology, with a focus on specialty medications.","keywords":[],"pubmed_id":"41533361","conclusions":"","publication_date":"2026-01-14T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.5498","URL":"https://doi.org/10.1001/jamadermatol.2025.5498","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2843771/jamadermatology_kong_2026_ld_250038_1767714992.46909.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Advanced Practice Clinicians and Dermatology Drug Spending"],"author":[{"given":"Edward L.","family":"Kong","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2026,1,14]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-14T16:00:41Z","timestamp":1768406441000,"date-parts":[[2026,1,14]]},"indexed":{"date-time":"2026-01-15T02:41:37Z","timestamp":1768444897323,"date-parts":[[2026,1,15]]},"subject":[],"abstract":"This economic evaluation study uses Medicare Part D data to assess the association between advanced practice clinicians and drug spending trends in dermatology, with a focus on specialty medications.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2843771"}},"subtitle":[],"deposited":{"date-time":"2026-01-14T16:00:42Z","timestamp":1768406442000,"date-parts":[[2026,1,14]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,1,14]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1001/jamadermatol.2023.1843","key":"dld250038r1","year":"2023","issue":"8","author":"Mohr","volume":"159","first-page":"859","unstructured":null,"article-title":"Trends over time in Medicare for advanced practice clinicians in dermatology, 2013-2020.","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2025.2142","key":"dld250038r2","year":"2025","issue":"10","author":"Kong","volume":"161","first-page":"1007","unstructured":null,"article-title":"Quantifying the role of specialty medications in Medicare Part D expenditures in dermatology.","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2017.5039","key":"dld250038r3","year":"2018","issue":"1","author":"Adamson","volume":"154","first-page":"30","unstructured":null,"article-title":"Geographic distribution of nonphysician clinicians who independently billed Medicare for common dermatologic services in 2014.","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.1026","key":"dld250038r4","year":"2022","issue":"6","author":"Arnold","volume":"158","first-page":"693","unstructured":null,"article-title":"Evaluation of the dermatology physician assistant workforce in the US.","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-023-02593-7","key":"dld250038r5","year":"2023","issue":"7","author":"Griffith","volume":"315","first-page":"2027","unstructured":null,"article-title":"Characteristics of physician associates/assistants in dermatology.","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.02.018","key":"dld250038r6","year":"2017","issue":"6","author":"Glazer","volume":"76","first-page":"1200","unstructured":null,"article-title":"Analysis of US dermatology physician assistant density.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,14]]},"references-count":6,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.5498","is_oa":true,"title":"Advanced Practice Clinicians and Dermatology Drug Spending","updated":"2026-01-18T01:04:10+00:00","published_date":"2026-01-14","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12805487/","pmh_id":"oai:pubmedcentral.nih.gov:12805487","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12805487/"}}},"created_at":"2026-01-18T22:40:12.285Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.5498","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5498","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5498","tag_type":"warning","value":"Only an abstract synopsis was provided and contains no results; details like timeframe, sample size, and effect sizes are unavailable.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.5498","tag_type":"warning","value":"Study design label is inferred from the abstract and may not reflect the full methods.","value_numeric":null}],"summaries":{"what_studied":"An economic evaluation used Medicare Part D data to assess how involvement of advanced practice clinicians is associated with dermatology drug spending trends, with a focus on specialty medications."}},{"doi":"10.1001/jamapediatrics.2025.5443","pmid":"41489825","title":"Private Equity in Autism Services","journal_title":"JAMA Pediatrics","journal_issn":"2168-6203","published_at":"2026-01-05T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12771383/","source_score":85,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-10","doi":"10.1001/jamapediatrics.2025.5443","days":"14","issn":"2168-6203","rank":"6","field":"Clinical Medicine","score":"85","category":"Pediatrics","categories":["Pediatrics"],"_categories":["Pediatrics"]},"pubmed":{"doi":"10.1001/jamapediatrics.2025.5443","title":"Private Equity in Autism Services.","journal":"JAMA pediatrics","methods":"","results":"","abstract":"This economic evaluation reports the number of therapeutic services for autism spectrum disorder that were acquired by private equity companies between 2015 and 2024.","keywords":[],"pubmed_id":"41489825","conclusions":"","publication_date":"2026-01-05T00:00:00"},"crossref":{"DOI":"10.1001/jamapediatrics.2025.5443","URL":"https://doi.org/10.1001/jamapediatrics.2025.5443","ISSN":["2168-6203"],"link":[{"URL":"https://jamanetwork.com/journals/jamapediatrics/articlepdf/2843100/jamapediatrics_arnold_2026_ld_250044_1765566789.26922.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Private Equity in Autism Services"],"author":[{"given":"Daniel R.","family":"Arnold","sequence":"first","affiliation":[{"name":"Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island"}]},{"given":"Megha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island"}]},{"given":"Jonathan","family":"Cantor","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}]},{"given":"Ryan K.","family":"McBain","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Insurance Research (HPI) at the Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}]},{"given":"Christopher M.","family":"Whaley","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island"}]},{"given":"Yashaswini","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island"}]}],"issued":{"date-parts":[[2026,1,5]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-05T16:00:33Z","timestamp":1767628833000,"date-parts":[[2026,1,5]]},"indexed":{"date-time":"2026-01-13T14:06:07Z","timestamp":1768313167376,"date-parts":[[2026,1,13]]},"subject":[],"abstract":"This economic evaluation reports the number of therapeutic services for autism spectrum disorder that were acquired by private equity companies between 2015 and 2024.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamapediatrics/fullarticle/2843100"}},"subtitle":[],"deposited":{"date-time":"2026-01-05T16:00:35Z","timestamp":1767628835000,"date-parts":[[2026,1,5]]},"issn-type":[{"type":"print","value":"2168-6203"}],"published":{"date-parts":[[2026,1,5]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1001/jamanetworkopen.2024.42218","key":"pld250044r1","year":"2024","issue":"10","author":"Grosvenor","volume":"7","first-page":null,"unstructured":null,"article-title":"Autism Diagnosis Among US Children and Adults, 2011-2022.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1542/peds.2020-0836","key":"pld250044r2","year":"2020","issue":"4","author":"McBain","volume":"146","first-page":null,"unstructured":null,"article-title":"State insurance mandates and the workforce for children with autism.","journal-title":"Pediatrics","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2023-075244","key":"pld250044r6","year":"2023","issue":null,"author":"Borsa","volume":"382","first-page":null,"unstructured":null,"article-title":"Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":null,"key":"pld250044r3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"PitchBook. Accessed September 1, 2025. https://pitchbook.com/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"pld250044r4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Autism data visualization tool. Centers for Disease Control and Prevention. Accessed 16 Sep 2025. https://www.cdc.gov/autism/data-research/autism-data-visualization-tool.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"pld250044r5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Batt? R, Appelbaum? E, Nguyen? QT. Pocketing money meant for kids: Private equity in autism services. Center for Economic & Policy Research. https://cepr. net/report/pocketing-money-meant-for-kids-private-equity-in-autism-services. 2023 Jun 21.","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Pediatrics"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,5]]},"references-count":6,"short-container-title":["JAMA Pediatr"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamapediatrics.2025.5443","is_oa":true,"title":"Private Equity in Autism Services","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-05","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12771383/","pmh_id":"oai:pubmedcentral.nih.gov:12771383","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12771383/"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"condition","value":"Autism Spectrum Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"warning","value":"Design listed as an economic evaluation, but the specific methodology and data sources were not described in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"warning","value":"Only a brief abstract statement was available; no numerical results or methods were provided to summarize.","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2025.5443","tag_type":"warning","value":"Population details and sample size were not reported in the excerpt.","value_numeric":null}],"summaries":{"what_studied":"An economic evaluation tallied the number of autism spectrum disorder therapeutic services acquired by private equity firms between 2015 and 2024."}},{"doi":"10.1001/jamadermatol.2025.3289","pmid":"40991306","title":"Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-09-24T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.3289","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-09-26","doi":"10.1001/jamadermatol.2025.3289","days":"7","issn":"2168-6068","rank":"6","field":"Clinical Medicine","score":"3","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.3289","title":"Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease.","journal":"JAMA dermatology","methods":"","results":"","abstract":"This economic evaluation examines the use, price, spending, and potential spending for roflumilast and apremilast from 2014 through 2024.","keywords":[],"pubmed_id":"40991306","conclusions":"","publication_date":"2025-09-24T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.3289","URL":"https://doi.org/10.1001/jamadermatol.2025.3289","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2839014/jamadermatology_perry_2025_ld_250023_1757437856.66777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease"],"author":[{"given":"Nikhita J.","family":"Perry","sequence":"first","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania, Philadelphia"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts"}]}],"issued":{"date-parts":[[2025,9,24]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-09-24T15:31:20Z","timestamp":1758727880000,"date-parts":[[2025,9,24]]},"indexed":{"date-time":"2025-09-25T00:16:50Z","timestamp":1758759410808,"date-parts":[[2025,9,25]]},"subject":[],"abstract":"This economic evaluation examines the use, price, spending, and potential spending for roflumilast and apremilast from 2014 through 2024.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2839014"}},"subtitle":[],"deposited":{"date-time":"2025-09-24T15:31:21Z","timestamp":1758727881000,"date-parts":[[2025,9,24]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,9,24]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.lanepe.2023.100639","key":"dld250023r1","year":"2023","issue":null,"author":"Gyldenløve","volume":"30","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).","journal-title":"Lancet Reg Health Eur","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.03.049","key":"dld250023r2","year":"2015","issue":"1","author":"Papp","volume":"73","first-page":"37","unstructured":null,"article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaneurol.2023.4514","key":"dld250023r4","year":"2024","issue":"1","author":"Kim","volume":"81","first-page":"85","unstructured":null,"article-title":"Potential Medicare and Medicaid savings on anti-CD20 therapy for multiple sclerosis.","journal-title":"JAMA Neurol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2024.1387517","key":"dld250023r5","year":"2024","issue":null,"author":"Spin","volume":"11","first-page":null,"unstructured":null,"article-title":"International regulatory and publicly-funded initiatives to advance drug repurposing.","journal-title":"Front Med (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamainternmed.2018.3931","key":"dld250023r6","year":"2018","issue":"11","author":"Moore","volume":"178","first-page":"1451","unstructured":null,"article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016.","journal-title":"JAMA Intern Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"dld250023r3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Ippolito? BLJ, Levy? J. Best practices using SSR Health net drug pricing data. Health Affairs Forefront. March 10, 2022. Accessed August 13, 2025. https://www.healthaffairs.org/content/forefront/best-practices-using-ssr-health-net-drug-pricing-data","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,24]]},"references-count":6,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.3289","is_oa":false,"title":"Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease","updated":"2025-09-25T02:42:03+00:00","published_date":"2025-09-24","best_oa_location":null}},"created_at":"2025-09-30T13:03:24.817Z","updated_at":"2025-10-03T07:07:01.912Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"condition","value":"Dermatologic Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"condition","value":"Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"generic","value":"apremilast","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"modality","value":"Phosphodiesterase 4 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"study_design","value":"Economic Evaluation","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"warning","value":"Only a brief abstract statement was provided; no numeric results or outcomes were available to summarize.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.3289","tag_type":"warning","value":"Specific data sources, methods, populations, and sample sizes were not described in the provided text.","value_numeric":null}],"summaries":{"what_studied":"An economic evaluation assessed use, prices, spending, and potential spending for the phosphodiesterase 4 inhibitors roflumilast and apremilast across 2014–2024."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"study_design","value":"Economic Evaluation"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study Designs","href":"/hub/tag/study_design"},{"name":"Economic Evaluation"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"study_design","hub_tag_value":"Economic Evaluation"}}}]]

Papers